Obama health reform plan slaps drugmakers

Back to TopCommentsE-mailPrintBookmark and Share

Health insurers aren’t the only companies in the sights of President Obama’s new health reform proposal.

Drugmakers such as Indianapolis-based Eli Lilly and Co. would shoulder an extra $1 billion in fees per year, up from the $2.3 billion they had already agreed to.

Also, Obama’s plan would allow the Federal Trade Commission to ban so-called pay-for-delay deals, in which makers of brand-name drugs pay generic drug companies to drop their patent challenges to brand-name drugs.

There were 66 such deals in the past five years, according to a January report by the FTC. Lilly wasn't named in the report. By extending the life of expensive brand-name drugs, such deals prevent American consumers from enjoying as much as $3.5 billion a year from low-cost generic drugs.

In December 2003, former Lilly CEO Sidney Taurel was quoted as saying that branded drugmakers could “truly eliminate the incentive in the calculation that generic companies would make” by launching their own generic versions of drugs before the generic maker had the chance to capitalize.

The pharmaceutical trade association, of which Lilly is a member, strongly opposes a ban on pay-for-delay deals.

In an earlier statement, it said, “Patent settlements between brand-name and generics companies can resolve expensive patent disputes to help foster innovation and improve access to medicines so that patients can live healthier, more productive lives.”



Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
thisissue1-092914.jpg 092914

Subscribe to IBJ